{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "group": "TDF/FTC",
                    "subjects": "2693",
                    "PYFU": "4386",
                    "analysis": "Original analysis on rate ratio scale"
                },
                "measures": "[incident HIV infections, incidence rate (per 100 PYFU), rate ratio (95% CI)]",
                "outcomes": "[11, 0.251, REF]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Original analysis on rate ratio scale",
                    "Group": "TDF/FTC",
                    "No. subjects": "2693",
                    "PYFU": "4386",
                    "Incident HIV infections": "11",
                    "Method": "Rate ratio analysis"
                },
                "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                "outcomes": "[0.251, REF]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "group": "TAF/FTC",
                    "subjects": "2694",
                    "PYFU": "4370",
                    "analysis": "Original analysis on rate ratio scale"
                },
                "measures": "[incident HIV infections, incidence rate (per 100 PYFU), rate ratio (95% CI)]",
                "outcomes": "[6, 0.137, 0.55 (0.20, 1.48)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Original analysis on rate ratio scale",
                    "Group": "TAF/FTC",
                    "No. subjects": "2694",
                    "PYFU": "4370",
                    "Incident HIV infections": "6",
                    "Method": "Rate ratio analysis"
                },
                "measures": "[Incidence rate (per 100 PYFU), Rate ratio (95% CI)]",
                "outcomes": "[0.137, 0.55 (0.20\u20131.48)]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "group": "TDF/FTC",
                    "PYFU": "4386",
                    "analysis": "Re-analysis using an averted infections framework",
                    "counterfactual placebo incidence rate": "2.06 per 100 PYFU",
                    "counterfactual placebo incidence rate note": "lower 2.5% credibility limit"
                },
                "measures": "[observed infections, predicted infections, averted infections, averted infections ratio (95% CI)]",
                "outcomes": "[11, 90.4, 79.4, REF]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TDF/FTC",
                    "PYFU": "4386",
                    "Observed infections": "11",
                    "Predicted infections": "90.4",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[79.4, REF]"
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "group": "TAF/FTC",
                    "PYFU": "4370",
                    "analysis": "Re-analysis using an averted infections framework",
                    "counterfactual placebo incidence rate": "2.06 per 100 PYFU",
                    "counterfactual placebo incidence rate note": "lower 2.5% credibility limit"
                },
                "measures": "[observed infections, predicted infections, averted infections, averted infections ratio (95% CI)]",
                "outcomes": "[6, 90.0, 84.0, 1.06 (0.96\u20131.17)]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "Analysis": "Re-analysis using an averted infections framework",
                    "Group": "TAF/FTC",
                    "PYFU": "4370",
                    "Observed infections": "6",
                    "Predicted infections": "90.0",
                    "Method": "Averted infections framework (using counterfactual placebo incidence rate of 2.06 per 100 PYFU)"
                },
                "measures": "[Averted infections, Averted infections ratio (95% CI)]",
                "outcomes": "[84.0, 1.06 (0.96-1.17)]"
            },
            "match": "yes"
        }
    ],
    "total_extracted_claims": 5,
    "total_ground_truth_claims": 4,
    "number_of_matches": 4
}